Through molecular docking, we further confirmed that Capillarisin exhibits a strong binding affinity for androgen receptors (ARs); further molecular dynamics simulations and binding free energy analyses showed that the binding between ARs and Capillarisin is stable, and the binding interaction is strong, indicating that Capillarisin is a significant potential candidate for the treatment of prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.